Stoke Therapeutics/$STOK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Stoke Therapeutics
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Ticker
$STOK
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
128
ISIN
US86150R1077
Website
STOK Metrics
BasicAdvanced
$632M
13.20
$0.88
1.20
-
Price and volume
Market cap
$632M
Beta
1.2
52-week high
$15.97
52-week low
$5.35
Average daily volume
614K
Financial strength
Current ratio
8.409
Quick ratio
8.01
Long term debt to equity
0.535
Total debt to equity
0.535
Profitability
EBITDA (TTM)
40.331
Gross margin (TTM)
100.00%
Net profit margin (TTM)
26.33%
Operating margin (TTM)
20.03%
Effective tax rate (TTM)
2.48%
Revenue per employee (TTM)
$1,490,000
Management effectiveness
Return on assets (TTM)
7.81%
Return on equity (TTM)
20.50%
Valuation
Price to earnings (TTM)
13.196
Price to revenue (TTM)
3.449
Price to book
1.8
Price to tangible book (TTM)
1.8
Price to free cash flow (TTM)
9.516
Free cash flow yield (TTM)
10.51%
Free cash flow per share (TTM)
121.59%
Growth
Revenue change (TTM)
2,333.81%
Earnings per share change (TTM)
-136.29%
3-year revenue growth (CAGR)
299.24%
3-year earnings per share growth (CAGR)
-29.81%
What the Analysts think about STOK
Analyst ratings (Buy, Hold, Sell) for Stoke Therapeutics stock.
Bulls say / Bears say
Stoke Therapeutics' lead candidate, zorevunersen (STK-001), has demonstrated substantial and durable reductions in seizure frequency and improvements in cognition and behavior in Dravet syndrome patients, indicating strong therapeutic potential. (investorplace.com)
The FDA has granted Breakthrough Therapy Designation for zorevunersen, facilitating expedited development and review processes, which could accelerate its path to market. (stocktitan.net)
Analysts have maintained a 'Strong Buy' rating for STOK, with an average 12-month price target of $26.00, suggesting significant upside potential from current levels. (stockanalysis.com)
Recent insider selling, including the CEO's sale of 10,382 shares, may signal a lack of confidence in the company's near-term prospects. (etfdailynews.com)
The departure of CEO Dr. Edward Kaye introduces leadership uncertainty, which could impact strategic direction and investor confidence. (stockanalysis.com)
Despite positive clinical data, the company reported a net loss of $25.7 million in Q2 2024, highlighting ongoing financial challenges that may necessitate additional funding. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
STOK Financial Performance
Revenues and expenses
STOK Earnings Performance
Company profitability
STOK News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Stoke Therapeutics stock?
Stoke Therapeutics (STOK) has a market cap of $632M as of June 20, 2025.
What is the P/E ratio for Stoke Therapeutics stock?
The price to earnings (P/E) ratio for Stoke Therapeutics (STOK) stock is 13.2 as of June 20, 2025.
Does Stoke Therapeutics stock pay dividends?
No, Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Stoke Therapeutics dividend payment date?
Stoke Therapeutics (STOK) stock does not pay dividends to its shareholders.
What is the beta indicator for Stoke Therapeutics?
Stoke Therapeutics (STOK) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.